Drug profile · INN
zenocutuzumab-zbco
BIZENGRI
zenocutuzumab-zbco (BIZENGRI) is a erbb-2/erbb-3 heterodimer inhibitor. Route of administration: solution. Current US regulatory status: approved.
Drug details — zenocutuzumab-zbco
- US status
- approved
- Class
- —
- Route
- SOLUTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
zenocutuzumab-zbco (BIZENGRI) is a erbb-2/erbb-3 heterodimer inhibitor. Route of administration: solution. Current US regulatory status: approved.
Key facts
Mechanism of action
ErbB-2/ErbB-3 heterodimer inhibitor
Primary target: ErbB-2/ErbB-3 heterodimer
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Frequently asked questions
What is zenocutuzumab-zbco?
zenocutuzumab-zbco (BIZENGRI) is a erbb-2/erbb-3 heterodimer inhibitor. Route of administration: solution. Current US regulatory status: approved.
What is the brand name for zenocutuzumab-zbco?
BIZENGRI is a marketed brand name for zenocutuzumab-zbco. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zenocutuzumab-zbco?
zenocutuzumab-zbco has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.